natalizumab, a multiple sclerosis agent and monoclonal antibody. ▪ INDICATIONS: This drug is used to treat ambulatory patients with relapsing-remitting multiple sclerosis who have not responded to other treatments. An unlabeled use is the treatment of Crohn’s disease. ▪ CONTRAINDICATIONS: Progressive multifocal leukoencephalopathy; murine protein allergy; immunodeficiency (in patients with HIV, AIDS, leukemia, lymphoma, and transplants); and known hypersensitivity to this drug prohibit its use. ▪ ADVERSE EFFECTS: Adverse effects of this drug include rigors, syncope, tremors, chest discomfort, hypertension, hypotension, abnormal liver function test, gastroenteritis, amenorrhea, vaginitis, urinary frequency, dermatitis, and pruritus. Life-threatening side effects include progressive multifocal leukoencephalopathy, suicidal ideation, anaphylaxis, and angioedema. Common side effects include headache, fatigue, depression, abdominal discomfort, urinary tract infection, irregular menses, rash, arthralgia, and lower respiratory tract infection.
